论文部分内容阅读
外周血造血干细胞是在预处理后能重建造血的干细胞来源之一。自身周血干细脆移植(AKSCT)已成功地应用于治疗各种不同类型的恶性淋巴造血疾病如白血病、淋巴瘤、多发性骨髓瘤及实体瘤如乳腺癌。作者在本文中比较了第一次完全缓解(CR_1)AML 患者移植自身外周血干细胞及体外净化骨髓(pABMT)中CFU-GM 数量和细胞组成对造血重建和无病生存(DFS)的影响。ABSCT:20例,使用阿糖胞苷(100mg/m~2,每12小时一次,1～5天)和柔红霉素(45mg/m~2,第3、4天)为动员剂,当白细胞达1×10~9/L、血小板达40×10~9/L 时收集外周血干细胞;pABMT:23例,骨髓体外用mafosfamide 净化。预处理方案41例为高分次全身照射(14.4GY)加环磷酰胺(200mg/kg),2例用马利兰(16mg/kg)和环磷酰胺。输注单个核细胞和CFU-GM:外周血分别为80×10~7/kg 和2.35×1~4/kg,骨髓分别为4.7×10~7/kg 和0.14×10~4/kg。
Peripheral blood stem cells are one of the sources of stem cells that can regenerate hematopoiesis after preconditioning. Autologous peripheral blood stem cell transplantation (AKSCT) has been successfully used in the treatment of various types of malignant lymphoid hematopoiesis such as leukemia, lymphoma, multiple myeloma and solid tumors such as breast cancer. The authors compared the effects of CFU-GM counts and cell composition on hematopoietic reconstitution and disease-free survival (DFS) in peripheral blood stem cells transplanted in patients with complete remission (CR_1) AML and in purified bone marrow (pABMT) in vitro. ABSCT: Twenty patients were mobilized with cytarabine (100 mg / m 2, once every 12 hours for 1 to 5 days) and daunorubicin (45 mg / m 2, days 3 and 4) Peripheral blood stem cells were collected when white blood cells reached 1 × 10 ~ 9 / L and platelets reached 40 × 10 ~ 9 / L; pABMT: 23 cases were purified with mafosfamide in vitro. Forty-one patients were treated with high-grade systemic irradiation (14.4GY) plus cyclophosphamide (200mg / kg) and two with malamin (16mg / kg) and cyclophosphamide. Infusion of mononuclear cells and CFU-GM: peripheral blood were 80 × 10 ~ 7 / kg and 2.35 × 1 ~ 4 / kg, bone marrow were 4.7 × 10 ~ 7 / kg and 0.14 × 10 ~ 4 / kg.